Ameriprise’s ClearPoint Neuro CLPT Stock Holding History

Ameriprise’s Portfolio CLPT Stock Details CLPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-13,861	Closed	-$165K	–	3987
2025 Q1	$165K	Sell	13,861 -27,455	-66%	-$427K	﹤0.01%	3817
2024 Q4	$635K	Buy	41,316 +2,742	+7%	+$35.5K	﹤0.01%	3430
2024 Q3	$432K	Buy	+38,574	New	+$369K	﹤0.01%	3536

Other funds holding CLPT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return

EIM

Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Lane Generational Dover, Massachusetts $126M AUM 53.89% 1-Year Est. Return

Ameriprise's CLPT Position: Q2 2025 in Review

Ameriprise sold out of ClearPoint Neuro (CLPT) in Q2 2025, closing a stake of 13,861 shares — an estimated $165K sold.

Ameriprise first reported a position in CLPT in Q3 2024 and held it in 3 quarters. The position peaked at $635K in Q4 2024. 96 funds tracked by Wall St. Rank hold CLPT as of Q2 2025.

Ameriprise reported no remaining ClearPoint Neuro position as of Q2 2025 after selling out during the quarter.
Ameriprise sold 13,861 ClearPoint Neuro shares in Q2 2025, an estimated $165K.
Ameriprise first reported a position in ClearPoint Neuro in Q3 2024 and held it in 3 quarters.
Ameriprise's ClearPoint Neuro position peaked at $635K in Q4 2024.
96 funds tracked by Wall St. Rank held ClearPoint Neuro as of Q2 2025.

Based on Ameriprise's 13F filing for Q2 2025, filed 14 Aug 2025.